) inked a deal with MedImmune, the global biologics research and
development arm of
). The companies have collaborated for a phase I/II study to
evaluate the efficacy and safety of AstraZeneca's MEDI4736 in
combination with Incyte's INCB24360 in cancer patients.
As per the agreement, the study will be co-funded equally by Incyte
and AstraZeneca but will be conducted by Incyte. The companies will
evaluate the combination in multiple solid tumors including
metastatic melanoma, non-small cell lung cancer, squamous cell
carcinoma of the head and neck and pancreatic cancer.
The phase I part of the study will establish a recommended dose
regimen of both MEDI4736 and INCB24360. The phase II part will
evaluate the safety and efficacy of the combination. Results from
the studies will determine whether further clinical development of
the combination is necessary.
We are encouraged by Incyte's collaboration with AstraZeneca.
Incyte already has a robust pipeline with several combination
studies are underway. Successful development and commercialization
of these candidates should drive growth.
Meanwhile, an abstract was posted at the American Society of
Clinical Oncology (ASCO) on a phase II study on Jakafi or placebo
) Xeloda (capecitabine) as second-line therapy in patients
suffering from metastatic pancreatic cancer. Data revealed that
Jakafi increased overall survival rate and progression-free
survival. However, both the results were not statistically
significant. We expect Incyte's shares to be negatively
Another abstract that was posted at the ASCO on a phase I/II
dose-escalation study evaluating INCB024360 in combination with
Yervoy (ipilimumab) in patients suffering from melanoma revealed
that out of the seven patients enrolled for the 300 mg dosage study
of INCB24360, five patients experienced clinically significant
elevations of alanine aminotransferase (ALT) after 30-76 days of
treatment. The enrolment for the study was stopped after that.
Moreover, one patient, having progressed on prior extensive liver
metastases, under the 25 mg treatment of INCB24360 experienced ALT
Incyte, a biopharmaceutical company, currently carries a Zacks Rank
#3 (Hold). Some better-ranked stocks in the sector include
Gilead Sciences Inc.
). The stock holds a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
INCYTE CORP (INCY): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis
To read this article on Zacks.com click here.